Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration
- 1 May 1997
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 37 (5) , 405-415
- https://doi.org/10.1002/j.1552-4604.1997.tb04318.x
Abstract
In this 2‐week, ascending dose study, the pharmacokinetic activity of sirolimus was examined in 40 stable renal transplant patients treated with cyclosporine and prednisone. Nine dose levels (range, 0.5–6.5 mg/m2/12 hr) of sirolimus were studied in a parallel design. Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 ± 1.2 hours; terminal half‐life, 62 ± 16 hours; oral dose clearance, 208 ± 95 mL/h/kg; apparent oral steady‐state volume of distribution, 12 ± 5 L/kg; and blood/plasma ratio, 38 ± 13. The intersubject variabilities in dose clearance, steady‐state volume of distribution, and blood/plasma ratio were 4.5‐fold. Preliminary assessments suggested linear dose proportionality. An excellent correlation existed between area under the concentration—time curve and trough blood concentration at steady state. Sirolimus did not produce any significant changes in area under the concentration—time curve of cyclosporine. Preliminary analysis suggested that values for the pharmacokinetic parameters of sirolimus vary among races (black versus nonblack) but not among genders.Keywords
This publication has 20 references indexed in Scilit:
- The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patientsKidney International, 1996
- Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapyMolecular Carcinogenesis, 1995
- The Synergistic Effects Of Cyclosporine, Sirolimus, And Brequinar On Heart Allograft Survival In MiceTransplantation, 1995
- A mammalian protein targeted by G1-arresting rapamycin–receptor complexNature, 1994
- STABILITY OF RENAL ALLOGRAFT GLOMERULAR FILTRATION RATE ASSOCIATED WITH LONG-TERM USE OF CYCLOSPORINE ATransplantation, 1993
- CYCLOSPORINE METABOLISM BY P450IIIA IN RAT ENTEROCYTES—ANOTHER DETERMINANT OF ORAL BIOAVAILABILITY?Transplantation, 1992
- RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTINGThe Lancet, 1989
- Characterization of Human Microsomal Cytochrome P-450 EnzymesAnnual Review of Pharmacology and Toxicology, 1989
- INDIVIDUALIZATION OF CYCLOSPORINE THERAPY USING PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERSTransplantation, 1985
- Estimation of Mean Residence Time from DataObtained when Multiple-Dosing Steady StateHas Been ReachedJournal of Pharmaceutical Sciences, 1984